Loading...
Changes in management for patients with lung cancer treated with radical radiotherapy during the first wave of the COVID-19 pandemic in the UK (COVID-RT Lung)
Banfill, Kathryn Price, G Wicks, K Britten, A. Carson, C. Hatton, M. Jayaprakash, K. T. Jegannathen, A. Lee, C. L. Panakis, N.
Banfill, Kathryn
Price, G
Wicks, K
Britten, A.
Carson, C.
Hatton, M.
Jayaprakash, K. T.
Jegannathen, A.
Lee, C. L.
Panakis, N.
Citations
Altmetric:
Abstract
Background: In response to the COVID-19 pandemic, guidelines on
reduced fractionation for patients with lung cancer treated with
curative-intent radiotherapy (RT) were published (Faivre-Finn et al)
aiming to reduce the number of hospital attendances and potential
exposure of vulnerable patients to SARS-CoV-2. Here we describe the
changes that have taken place.
Methods: COVID-RT Lung is a prospective multicentre UK data
collection. Inclusion criteria are: patients with stage 1–3 lung cancer
(biopsy-proven or diagnosed on cross-sectional imaging) referred for
and/or treated with radical RT between 2/4/2020–2/10/2020. Both
patients who had a change in their management and those who continue
with standard management are included. Data on demographics, COVID-
19 diagnosis, diagnostic work-up, RT and systemic treatment, treatmentrelated
toxicity, disease/patient status are collected. Each participating
centre obtains local approval and anonymised data is collected on a
central, cloud-based Research Electronic Data Capture system.
Results: 1117 records from 20 UK RT siteswere available for analysis on
30/11/2020. 562 (50%) female, median age 72 years (38–93 years). 15
patients (1%) were diagnosed with COVID-19, 9 prior to treatment. 160
patients (14%) had their diagnostic investigations affected by the
pandemic. 415 patients (37%) had their treatment changed from their
centre’s standard of care (table). Patients with PS0-1 were more likely to
have their treatment changed compared to patients with a poorer PS.
The median number of RT fractionswas 15 for patients who had their RT
dose/fractionation changed compared to 20 for those who were treated
as per standard of care. Conclusions: This nationwide cohort shows that clinicians in the UK
changed the management of patients with stage 1–3 lung cancer in line
with national guidelines. The main changes are a reduction in
chemotherapy use and an increase in RT hypofractionation.
Description
Date
2021
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 206.16 KB
Keywords
Type
Meetings and Proceedings
Citation
Banfill K, Price G, Wicks K, Britten A, Carson C, Hatton M, et al. 203MO Changes in management for patients with lung cancer treated with radical radiotherapy during the first wave of the COVID-19 pandemic in the UK (COVID-RT Lung). Journal of Thoracic Oncology. 2021 Apr;16(4):S808.